Case Study
Actionable results to inform your treatment decisions
PrismRA® identifies a patient’s likelihood of response to TNF inhibitor (TNFi) therapies. Even patients with similar clinical presentations can vary widely in their likelihood of inadequately responding to medications.
This below case study offers an example of two similar patients with rheumatoid arthritis (RA) whose providers administered the PrismRA test to help guide their treatment decisions.
Case Study
Two similar female patients with RA failed to control their symptoms with conventional DMARDs for 3 consecutive months. Both patients are now considering starting their first targeted therapy.
Case Study
Two similar female patients with RA failed to control their symptoms with conventional DMARDs for 3 consecutive months. Both patients are now considering starting their first targeted therapy.


Patient's PrismRA results and proposed treatment decisions